Mount Sinai researchers just published research that could represent a potential breakthrough in the battle against cancer. They have developed an “in situ” vaccination which they use to inject immune stimulants directly into a tumor to program the immune system to destroy the tumor and other similar tumors within the host. They experimented on mice in preclinical studies and then conducted a small clinical trial with 11 participants. The results were extremely promising and Mount Sinai now is conducting new vaccine studies for lymphoma, breast and head and neck cancer patients. They are also testing for liver and ovarian cancer.
The study was sponsored by The Damon Runyon Cancer Research Foundation, the Cancer Research Institute and Merck. Celldex and Oncovir provided reagents for the clinical trial and the lab work.
Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai